Artiva Biotherapeutics (NASDAQ:ARTV) Given New $18.00 Price Target at Needham & Company LLC

Artiva Biotherapeutics (NASDAQ:ARTV) had its price target decreased by Needham & Company LLC from $23.00 to $18.00 in a research report report published on Thursday,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

A number of other equities research analysts have also weighed in on the stock. Wedbush reaffirmed an “outperform” rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a research note on Tuesday, March 25th. Cantor Fitzgerald cut their price objective on Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 25th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Artiva Biotherapeutics in a report on Wednesday, March 26th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Artiva Biotherapeutics has an average rating of “Buy” and a consensus target price of $19.40.

Artiva Biotherapeutics Trading Up 17.7%

NASDAQ ARTV opened at $2.13 on Thursday. Artiva Biotherapeutics has a fifty-two week low of $1.78 and a fifty-two week high of $17.31. The stock has a 50 day simple moving average of $2.95 and a two-hundred day simple moving average of $6.64.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Thursday, May 8th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.15). On average, sell-side analysts expect that Artiva Biotherapeutics will post -4.95 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. bought a new position in shares of Artiva Biotherapeutics during the fourth quarter valued at approximately $52,000. Wells Fargo & Company MN grew its stake in shares of Artiva Biotherapeutics by 64.0% in the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after buying an additional 3,361 shares during the last quarter. BNP Paribas Financial Markets increased its position in Artiva Biotherapeutics by 262.1% during the 4th quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company’s stock valued at $100,000 after buying an additional 7,151 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in Artiva Biotherapeutics during the third quarter valued at $166,000. Finally, Barclays PLC bought a new stake in Artiva Biotherapeutics in the third quarter worth $304,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.